Spondyloarthritis & psoriatic arthritis
Cardiometabolic Effects of Apremilast in Patients With Psoriatic Arthritis: A Prospective Cohort Study
Authors' conclusion
This study demonstrates that apremilast reduces fat mass in patients with PsA and suggests beneficial CV and metabolic effects, potentially reducing the risk of CV events.
Study context
- Population
- Adults with active psoriatic arthritis (PsA) initiating apremilast17 completed
- Participants
- 44 adults
- Outcome
- Body composition assessed by DXA
- Follow-up
- 52 weeks
Methodological detailslongitudinal, nonrandomized, multicenter, mixed models adjusted for relevant covariates
- Longitudinal
- Nonrandomized
- Multicenter
- Mixed models adjusted for relevant covariates
Main finding
As reported in the abstract
Body composition (DXA), change after 1 year
Total fat, change (P = 0.005)
−7.4 kg
Android fat, change (P = 0.002)
−1.1 kg
Observational data: associations, not effects.
Secondary outcomes
Disease activity (DAS28-CRP), change · 1 year
- DAS28-CRP change (P = 0.01)
- −0.6
Blood pressure (BP), lipids, intima-media thickness, glucose
- BP showed minor reduction
- Lipids, intima-media thickness and glucose did not change
Correlation of android fat with disease activity reduction
- R (P = 0.004)
- 0.31
Safety
Discontinuation due to ineffectiveness or side effects
- 27 of 44 patients discontinued due to ineffectiveness or side effects; 17 completed the study
Original publication
Cardiometabolic Effects of Apremilast in Patients With Psoriatic Arthritis: A Prospective Cohort Study. J Rheumatol. Published 15 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →